News | Ablation Systems | May 10, 2018

Imricor MRI-Guided Cardiac Ablation Study Results to Be Presented at HRS 2018

Single-center study evaluated use of real-time MRI guidance during ablation treatment for atrial flutter

Imricor MRI-Guided Cardiac Ablation Study Results to Be Presented at HRS 2018

May 10, 2018 — Results from the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of atrial flutter under real-time magnetic resonance imaging (MRI) guidance will be presented at the 2018 Heart Rhythm Society (HRS) conference, May 9-12 in Boston. Philipp Sommer, M.D., will present the study results.

The single-center study enrolled 35 patients and was sponsored by the University of Leipzig Heart Center in Leipzig, Germany. Prof. Gerhard Hindricks, M.D., head of the Department of Electrophysiology at the Helios Leipzig Heart Center, was the principal investigator. Results from the study will be submitted to support the CE mark approval process for the Vision-MR Ablation Catheter. Publication of study results will follow later this spring.

Imricor’s Vision-MR Ablation Catheter, when used with the Advantage-MR EP Recorder/Stimulator System, allows physicians to perform cardiac ablations under MRI guidance, offering a radiation-free environment for patients and physicians. Intraprocedural MR imaging allows for real-time soft tissue imaging of the cardiac anatomy and substrate. This has the potential to improve first-time success rates of ablation procedures by providing lesion visualization and verification. In addition, real-time assessment of the cardiac substrate has the potential to allow physicians to deliver individualized ablation strategies.

The Advantage-MR EP Recorder/Stimulator System has received CE mark approval; it has not yet been approved for use in the United States. The Vision-MR Ablation Catheter has been approved as an investigational device for clinical studies in Europe. All other Imricor devices are not yet approved for use in humans.

For more information: www.imricor.com

 

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
Overlay Init